Skip to main content

Columvi Dosage

Generic name: GLOFITAMAB 10mg in 10mL
Dosage form: injection, concentrate
Drug class: Bispecific T-cell engagers (BiTE)

Medically reviewed by Drugs.com. Last updated on Jun 18, 2025.

Important Dosing Information

  • Administer only as an intravenous infusion through a dedicated infusion line that includes a sterile 0.2-micron in-line filter.
  • ​Administer COLUMVI diluted solution via intravenous bag infusion. The 2.5 mg dose may alternatively be administered via intravenous syringe infusion.
  • COLUMVI should only be administered by a healthcare professional with immediate access to appropriate medical support, including supportive medications to manage severe CRS.
  • Ensure adequate hydration before administering COLUMVI.
  • Premedicate before each dose.
  • Following pretreatment with obinutuzumab, administer COLUMVI according to the step-up dosing schedule in Table 1 with appropriate premedication, including dexamethasone, to reduce the incidence and severity of CRS.
  • Due to the risk of CRS, patients should be hospitalized during and for 24 hours after completion of infusion of step-up dose 1 (2.5 mg on Cycle 1 Day 8).
  • Patients who experienced any grade CRS during step-up dose 1 should be hospitalized during and for 24 hours after completion of step-up dose 2 (10 mg on Cycle 1 Day 15). CRS with step-up dose 2 can occur in patients who did not experience CRS with step-up dose 1.
  • For subsequent doses, patients who experienced Grade ≥ 2 CRS with their previous infusion should be hospitalized during and for 24 hours after the completion of the next COLUMVI infusion.

Recommended Dosage

Pretreatment with Obinutuzumab

Pretreat all patients with a single 1,000 mg dose of obinutuzumab administered as an intravenous infusion on Cycle 1 Day 1, 7 days prior to initiation of COLUMVI (see Table 1) to deplete the circulating and lymphoid tissue B cells.

Obinutuzumab should be administered as an intravenous infusion at 50 mg/hour. The rate of infusion can be escalated in 50 mg/hour increments every 30 minutes to a maximum of 400 mg/hour. Refer to the obinutuzumab prescribing information for complete dosing information.

COLUMVI Step-up Dose Schedule

COLUMVI dosing begins with a step-up dose schedule. Following completion of pretreatment with obinutuzumab on Cycle 1 Day 1, administer COLUMVI as an intravenous infusion according to the step-up dose schedule in Table 1. Administer premedications for each dose of COLUMVI as described in Table 3.

Table 1: COLUMVI Dosing Schedule (21-Day Treatment Cycles)
Treatment cycle Day Dose of COLUMVI Duration of infusion
*
Refer to "Pretreatment with obinutuzumab" described above.
†
For patients who experience CRS with their previous dose of COLUMVI, the time of infusion may be extended up to 8 hours.
‡
If the patient experienced CRS with the previous dose, the duration of infusion should be maintained at 4 hours.
Cycle 1 Day 1 Obinutuzumab*
Day 8 Step-up dose 1 2.5 mg 4 hours†
Day 15 Step-up dose 2 10 mg
Cycle 2 Day 1 30 mg 4 hours†
Cycle 3 to 12 Day 1 30 mg 2 hours‡

Continue COLUMVI for a maximum of 12 cycles (inclusive of Cycle 1 step-up dosing) or until disease progression or unacceptable toxicity, whichever occurs first.

Monitoring for Cytokine Release Syndrome

  • Administer the COLUMVI infusions intravenously in a healthcare setting with immediate access to medical support to manage CRS, including severe CRS.
  • For the first COLUMVI step-up dose (2.5 mg on Cycle 1 Day 8), patients should be hospitalized during and for 24 hours after completion of the COLUMVI infusion.
  • Patients who experienced any grade CRS during step-up dose 1 should be hospitalized during and for 24 hours after completion of step-up dose 2 (10 mg on Cycle 1 Day 15). CRS with step-up dose 2 can occur in patients who did not experience CRS with step-up dose 1.
  • For subsequent infusions (30 mg on Day 1 of Cycle 2 or subsequent cycles), patients who experienced Grade ≥ 2 CRS with their previous infusion should be hospitalized during and for 24 hours after completion of the next COLUMVI infusion.
  • For monitoring after delayed or missed doses of COLUMVI, follow the recommendations in Table 2.

Delayed or Missed Doses

If a dose of COLUMVI is delayed, restart therapy based on the recommendations made in Table 2, then resume the treatment schedule accordingly.

For repeat of the 2.5 mg dose patients should be hospitalized during and for 24 hours after completion of the COLUMVI infusion. For the repeat of the 10 mg dose, patients should be hospitalized during and for 24 hours after completion of the COLUMVI infusion if any grade CRS occurred during the most recent 2.5 mg dose.

Table 2: Recommendations for Restarting COLUMVI After Dose Delay
Last Dose Administered Time Since Last Dose Administered Action for Next Dose(s)*
*
Administer premedication as per Table 3 for all patients.
†
Patients should be hospitalized during and for 24 hours after completing infusion of the 2.5 mg dose.
‡
Patients should be hospitalized during and for 24 hours after completing infusion of the 10 mg dose if CRS occurred during the most recent 2.5 mg dose.
Obinutuzumab pretreatment (Cycle 1 Day 1) ≤ 2 weeks
  • Administer COLUMVI 2.5 mg (Cycle 1 Day 8)†, then resume the planned treatment schedule.
> 2 weeks
  • Repeat obinutuzumab 1,000 mg pretreatment (Cycle 1 Day 1).
  • Then administer COLUMVI 2.5 mg (Cycle 1 Day 8)† and resume the planned treatment schedule.
COLUMVI 2.5 mg
(Cycle 1 Day 8)		 ≤ 2 weeks
  • Administer COLUMVI 10 mg (Cycle 1 Day 15)‡, then resume the planned treatment schedule.
> 2 to ≤ 4 weeks
  • Repeat COLUMVI 2.5 mg (Cycle 1 Day 8)†.
  • Then administer COLUMVI 10 mg (Cycle 1 Day 15)‡ and resume the planned treatment schedule.
> 4 weeks
  • Repeat obinutuzumab 1,000 mg pretreatment (Cycle 1 Day 1) and COLUMVI 2.5 mg (Cycle 1 Day 8)†.
  • Then administer COLUMVI 10 mg (Cycle 1 Day 15)‡ and resume the planned treatment schedule.
COLUMVI 10 mg
(Cycle 1 Day 15)		 ≤ 2 weeks
  • Administer COLUMVI 30 mg (Cycle 2 Day 1), then resume the planned treatment schedule.
> 2 to ≤ 6 weeks
  • Repeat COLUMVI 10 mg (Cycle 1 Day 15).‡
  • Then administer COLUMVI 30 mg (Cycle 2 Day 1) and resume the planned treatment schedule.
> 6 weeks
  • Repeat obinutuzumab 1,000 mg pretreatment (Cycle 1 Day 1), COLUMVI 2.5 mg (Cycle 1 Day 8)†, and COLUMVI 10 mg (Cycle 1 Day 15)‡.
  • Then administer COLUMVI 30 mg (Cycle 2 Day 1) and resume the planned treatment schedule.
COLUMVI 30 mg
(Cycle 2 onwards)		 ≤ 6 weeks
  • Administer COLUMVI 30 mg, then resume the planned treatment schedule.
> 6 weeks
  • Repeat the Cycle 1 regimen described in Table 1: obinutuzumab 1,000 mg pretreatment (Day 1), COLUMVI 2.5 mg (Day 8)†, and COLUMVI 10 mg (Day 15)‡.
  • Then administer COLUMVI 30 mg (Day 1 of next cycle) and resume the planned treatment schedule.

Recommended Premedication and Prophylactic Medications

Premedication

Administer the following premedications to reduce the risk of CRS and infusion-related reactions.

Table 3: Premedications to be Administered for COLUMVI Infusion
Day of Treatment Cycle Patients requiring premedication Premedication Administration
*
If dexamethasone is not available, administer prednisone 100 mg, prednisolone 100 mg, or methylprednisolone 80 mg intravenously.
Cycle 1, Day 8 and Day 15; Cycle 2; Cycle 3 Dexamethasone 20 mg intravenously* Completed at least 1 hour prior to COLUMVI infusion.
All patients Acetaminophen 500 mg to 1,000 mg orally At least 30 minutes before COLUMVI infusion.
Antihistamine (diphenhydramine 50 mg orally or intravenously or equivalent) Completed at least 30 minutes before COLUMVI infusion.
All subsequent infusions All patients Acetaminophen 500 mg to 1,000 mg orally At least 30 minutes before COLUMVI infusion.
Antihistamine (diphenhydramine 50 mg orally or intravenously or equivalent) Completed at least 30 minutes before COLUMVI infusion.
Patients who experienced any grade CRS with the previous dose Dexamethasone 20 mg intravenously* Completed at least 1 hour prior to COLUMVI infusion.

Tumor Lysis Syndrome Prophylaxis

Before starting COLUMVI, administer anti-hyperuricemics to patients at risk of tumor lysis syndrome, ensure adequate hydration status, and monitor as appropriate.

Antiviral Prophylaxis

Before starting COLUMVI, consider initiation of antiviral prophylaxis to prevent herpes virus reactivation. Consider prophylaxis for cytomegalovirus infection in patients at increased risk.

Pneumocystis jirovecii Pneumonia (PJP)

Consider PJP prophylaxis prior to starting COLUMVI in patients at increased risk.

Dosage Modifications for Adverse Reactions

No dosage reduction for COLUMVI is recommended.

Cytokine Release Syndrome

Identify CRS based on clinical presentation. Evaluate for and treat other causes of fever, hypoxia, and hypotension.

If CRS is suspected, withhold COLUMVI and manage according to the recommendations in Table 4 and current practice guidelines. Administer supportive care for CRS, which may include intensive care for severe or life-threatening cases.

Table 4: Recommendations for Management of Cytokine Release Syndrome
Grade* Presenting Symptoms Actions
*
American Society for Transplantation and Cellular Therapy (ASTCT) 2019 consensus grading criteria.
†
Premedication may mask fever. Therefore, if clinical presentation is consistent with CRS, follow these management guidelines.
‡
Duration of infusion may be extended up to 8 hours, as appropriate for that cycle (see Table 1).
§
Refer to Table 2 for information on restarting COLUMVI after dose delays.
Low-flow oxygen defined as oxygen delivered at < 6 L/minute, high-flow oxygen defined as oxygen delivered at ≥ 6 L/minute.
Grade 1 Temperature ≥ 100.4°F (38°C)†
  • Withhold COLUMVI and manage per current practice guidelines.
    • If symptoms resolve, restart infusion at a slower rate.‡
  • Ensure CRS symptoms are resolved for at least 72 hours before next dose.§
  • Consider slower infusion rate for next dose.
Grade 2 Temperature ≥ 100.4°F (38°C)† with:
Hypotension not requiring vasopressors
and/or
Hypoxia requiring low-flow oxygen by nasal cannula or blow-by
  • Withhold COLUMVI and manage per current practice guidelines.
    • If symptoms resolve, restart infusion at a slower rate.‡
  • Ensure CRS symptoms are resolved for at least 72 hours before next dose.§
  • For the next dose, consider a slower infusion rate, monitor more frequently, and consider hospitalization.
  • For recurrent Grade 2 CRS, manage per Grade 3 CRS.
Grade 3 Temperature ≥ 100.4°F (38°C)† with:
Hypotension requiring vasopressor (with or without vasopressin)
and/or
Hypoxia requiring high-flow oxygen by nasal cannula, face mask, non-rebreather mask, or Venturi mask
  • Withhold COLUMVI and manage per current practice guidelines, which may include intensive care.
  • Ensure CRS symptoms are resolved for at least 72 hours before next dose.§
  • Hospitalize for the next dose, monitor more frequently, and consider a slower infusion rate.‡
  • For recurrent Grade 3 CRS, permanently discontinue COLUMVI.
Grade 4 Temperature ≥ 100.4°F (38°C)† with:
Hypotension requiring multiple vasopressors (excluding vasopressin)
and/or
Hypoxia requiring oxygen by positive pressure (e.g., CPAP, BiPAP, intubation, and mechanical ventilation)
  • Permanently discontinue COLUMVI and manage per current practice guidelines, which may include intensive care.

Neurologic Toxicity, Including ICANS

Management recommendations for neurologic toxicity, including ICANS, is summarized in Table 5. At the first sign of neurologic toxicity, including ICANS, consider neurology evaluation and withholding COLUMVI based on the type and severity of neurotoxicity. Rule out other causes of neurologic symptoms. Provide supportive therapy, which may include intensive care.

Table 5: Recommended Dosage Modification for Neurologic Toxicity (Including ICANS)
Adverse Reaction Severity*,† Actions
*
Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.03.
†
Based on ASTCT 2019 grading for ICANS.
‡
Consider the type of neurologic toxicity before deciding to withhold COLUMVI.
§
See Dosage and Administration (2.2) on restarting COLUMVI after dose delays.
Evaluate benefit-risk before restarting COLUMVI.
Grade 1
  • Continue COLUMVI and monitor neurologic toxicity symptoms.
  • If ICANS, manage per current practice guidelines.
Grade 2
  • Withhold COLUMVI until neurologic toxicity symptoms improve to Grade 1 or baseline.‡, §
  • Provide supportive therapy, and consider neurologic evaluation.
  • If ICANS, manage per current practice guidelines.
Neurologic Toxicity* (including ICANS†) Grade 3
  • Withhold COLUMVI until neurologic toxicity symptoms improve to Grade 1 or baseline for at least 7 days.§,
  • For Grade 3 neurologic events lasting more than 7 days, consider permanently discontinuing COLUMVI.
  • Provide supportive therapy, and consider neurology evaluation.
  • If ICANS, manage per current practice guidelines.
Grade 4
  • Permanently discontinue COLUMVI.
  • Provide supportive therapy, which may include intensive care, and consider neurology evaluation.
  • If ICANS, manage per current practice guidelines.

Other Adverse Reactions

Table 6: Recommended Dosage Modifications for Other Adverse Reactions
Adverse Reactions* Severity* Actions
*
Based on NCI CTCAE, version 4.03.
†
See Dosage and Administration (2.2) on restarting COLUMVI after dose delays.
Infections Grades 1 – 4
  • Withhold COLUMVI in patients with active infection until the infection resolves.†
  • For Grade 4, consider permanent discontinuation of COLUMVI.
Grade 1
  • Monitor for signs and symptoms of compression or obstruction due to mass effect secondary to tumor flare.
Tumor flare Grades 2 – 4
  • Monitor for signs and symptoms of compression or obstruction due to mass effect secondary to tumor flare, and institute appropriate treatment including antihistamine and corticosteroids.
  • Withhold COLUMVI until tumor flare resolves.†
Neutropenia Absolute neutrophil count less than 0.5 × 109/L
  • Withhold COLUMVI until absolute neutrophil count is 0.5 × 109/L or higher.†
Thrombocytopenia Platelet count less than 50 × 109/L
  • Withhold COLUMVI until platelet count is 50 × 109/L or higher.†
Other Adverse Reactions Grade 3 or higher
  • Withhold COLUMVI until the toxicity resolves to Grade 1 or baseline.†

Preparation into an Intravenous Bag

​This section describes preparation of all doses of COLUMVI into an intravenous bag. For preparation instructions for the 2.5 mg dose into an intravenous syringe, see subsection 2.6.

​Preparation

  • ​Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. COLUMVI is a colorless clear solution. Discard the vial if the solution is cloudy, discolored, or contains visible particles.
  • ​Use aseptic technique when preparing the COLUMVI diluted solution for intravenous infusion.

​Dilution for Intravenous Bag Infusion

  • ​Determine the dose, total volume of COLUMVI solution, and the number of COLUMVI vials needed (see Table 7).
  • ​Select an appropriate size infusion bag of 0.9% Sodium Chloride Injection or 0.45% Sodium Chloride Injection (see Table 7).
    • COLUMVI diluted with 0.9% Sodium Chloride Injection is compatible with intravenous infusion bags composed of polyvinyl chloride (PVC), polyethylene (PE), polypropylene (PP) or polyolefin.
    • COLUMVI diluted with 0.45% Sodium Chloride Injection is compatible with intravenous infusion bags composed of PVC.
  • ​Prepare the infusion bag by withdrawing and discarding the volume from the infusion bag according to Table 7.
  • ​Withdraw the required volume of COLUMVI from the vial(s) using a sterile needle and syringe and dilute into the infusion bag to a final concentration of 0.1 mg/mL to 0.6 mg/mL according to Table 7.
Table 7: Dilution of COLUMVI into an intravenous infusion bag
​Dose of COLUMVI Size of 0.9% Sodium Chloride Injection or 0.45% Sodium Chloride Injection infusion bag Volume to be withdrawn and discarded from the infusion bag Volume of COLUMVI to be added to the infusion bag Total volume to be infused
​2.5 mg 50 mL 27.5 mL 2.5 mL 25 mL
​10 mg 50 mL 10 mL 10 mL 50 mL
100 mL 10 mL 10 mL 100 mL
​30 mg 50 mL 30 mL 30 mL 50 mL
100 mL 30 mL 30 mL 100 mL
  • ​Discard any unused COLUMVI left in the vial.
  • ​Gently invert the infusion bag to mix the solution, in order to avoid excess foaming. Do not shake.

Preparation of 2.5 mg Dose into an Intravenous Syringe

​This section describes the alternative method of preparation of the 2.5 mg dose of COLUMVI into an intravenous syringe. For preparation instructions for all doses into an intravenous infusion bag, see subsection 2.5.

​Preparation

  • ​Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. COLUMVI is a colorless clear solution. Discard the vial if the solution is cloudy, discolored, or contains visible particles.
  • ​Use aseptic technique when preparing the COLUMVI diluted solution for intravenous syringe infusion.

​Dilution for Intravenous Syringe Infusion (Alternative Method for 2.5 mg Dose Only)

  • ​Draw 22.5 mL of 0.9% Sodium Chloride Injection or 0.45% Sodium Chloride Injection into a 30 mL syringe composed of PP (see Table 8).
  • ​Withdraw 2.5 mL of COLUMVI from the vial using a sterile needle into a second syringe (see Table 8). Discard any unused COLUMVI left in the vial.
  • ​Attach a connector to the two syringes and transfer COLUMVI into the 30 mL syringe. The final concentration of COLUMVI should be 0.1 mg/mL.
Table 8: Dilution of COLUMVI into an intravenous syringe
​Dose of COLUMVI Volume of 0.9% Sodium Chloride Injection or 0.45% Sodium Chloride Injection to be added to the syringe Volume of COLUMVI to be added to the syringe Total volume to be infused
​2.5 mg 22.5 mL 2.5 mL 25 mL
  • ​Disconnect the syringes. Draw air into the syringe containing the COLUMVI diluted solution and close.
  • ​Gently invert the syringe to mix the solution, in order to avoid excessive foaming. Do not shake.
  • ​Remove air bubbles from the syringe before administration.

Storage and Administration

​Storage of Diluted Product

​Immediately use diluted COLUMVI solution. If not used immediately, the diluted solution can be stored:

  • ​Refrigerated at 2°C to 8°C (36°F to 46°F) for up to 64 hours, or
  • ​At room temperature up to 25°C (77°F) for up to 4 hours.

​Do not freeze the diluted infusion solution.

​Discard diluted infusion solution if storage time exceeds these limits.

​COLUMVI Administration

  • ​Administer COLUMVI as an intravenous infusion only through a dedicated infusion line that includes a sterile 0.2-micron in-line filter using an intravenous infusion pump or syringe pump. Prime the infusion line with the diluted infusion solution.
  • ​No incompatibilities have been observed with infusion sets with product-contacting surfaces of polyurethane (PUR), PVC, PE, polybutadiene (PBD), polyetherurethane (PEU), polycarbonate (PC), silicone, polytetrafluoroethylene (PTFE), or acrylonitrile butadiene styrene (ABS), and in-line filter membranes composed of polyethersulfone (PES) or polysulfone.
  • ​See Table 1 for duration of infusion. The maximum time for the administration of the diluted infusion solution may be extended up to 8 hours (see Table 4).
  • ​To ensure the entire dose of COLUMVI is administered, replace the empty infusion bag or syringe with an infusion bag or syringe containing 0.9% Sodium Chloride Injection or 0.45% Sodium Chloride Injection connected to the same infusion line. Continue the infusion at the same rate until the recommended infusion duration is reached according to Table 1.
  • ​Do not mix COLUMVI with other drugs.

Does Columvi interact with my other drugs?

Enter medications to view a detailed interaction report using our Drug Interaction Checker.

Frequently asked questions

See also:

Rituxan

Rituxan infusion is used to treat certain leukemias and lymphomas and some non-cancer conditions ...

Reviews & ratings
8.2 / 10
53 Reviews
View more

Monjuvi

Monjuvi is used for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or follicular ...

Reviews & ratings
1 Reviews
View more

Truxima

Truxima is used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid ...

Reviews & ratings
4 Reviews
View more

Breyanzi

Breyanzi is a CAR T cell therapy for large B-cell lymphoma, CLL/SLL, follicular lymphoma, mantle ...

Reviews & ratings
Add a review
View more

Kymriah

Kymriah is used to treat B-cell precursor acute lymphoblastic leukemia (ALL), large B-cell ...

Reviews & ratings
Add a review
View more

Polivy

Polivy (polatuzumab vedotin-piiq) is a targeted treatment that may be used to treat diffuse large ...

Reviews & ratings
Add a review
View more

Yescarta

Yescarta is used to treat large B-cell lymphoma and follicular lymphoma (FL) in adults. It is a p ...

Reviews & ratings
Add a review
View more

Zynlonta

Zynlonta (loncastuximab tesirine) is used to treat relapsed or refractory diffuse large B-cell ...

Reviews & ratings
Add a review
View more

Xpovio

Xpovio is used to treat multiple myeloma (MM) or relapsed/refractory diffuse large B-cell lymphoma ...

Reviews & ratings
Add a review
View more

Tazverik

Tazverik (tazemetostat) used for the treatment of patients with epithelioid sarcoma and follicular ...

Reviews & ratings
2 Reviews
View more

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer